Text Size

Study of Medical Treatment for Methamphetamine Addiction (BUP PGx)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
National Institute on Drug Abuse (NIDA)
Information provided by (Responsible Party):
Keith Heinzerling, University of California, Los Angeles
ClinicalTrials.gov Identifier:
NCT00833443
First received: January 30, 2009
Last updated: January 14, 2013
Last verified: January 2013
History of Changes

January 30, 2009
January 14, 2013
January 2009
December 2012   (final data collection date for primary outcome measure)
Clinical phenotype of frequency of baseline MA use in 30 days preceding the baseline period using self-report and results of thrice weekly urine drug screens for MA metabolites during baseline. [ Time Frame: Weekly ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00833443 on ClinicalTrials.gov Archive Site
Clinical phenotype of treatment response to bupropion on MA use during the medication phase, as measured via self-reported MA use and thrice weekly urine screens for MA metabolites. [ Time Frame: 12 weeks ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
Study of Medical Treatment for Methamphetamine Addiction
Pharmacogenomics and Medication Development for Methamphetamine Dependence

Currently there are no medications approved for the treatment of methamphetamine addiction. Bupropion is an antidepressant that is approved by the Food and Drug Administration (FDA) for the treatment of depression and for cigarette smoking cessation but is not approved by the FDA for the treatment of methamphetamine addiction. Preliminary research studies suggest that bupropion may help people receiving treatment for methamphetamine addiction to reduce or to stop their methamphetamine use. But results of these studies also suggest that bupropion may help certain groups of patients more than others, such as men versus women and light versus heavy methamphetamine users, although the reasons for this difference are not known. One possibility is that a person's genetic make up may influence whether or not they respond to treatment with bupropion for methamphetamine addiction.

The purpose of the study is to determine if bupropion is can help people reduce or stop their methamphetamine use and to investigate whether genetic variations influence whether people respond to treatment with bupropion for methamphetamine addiction, which may help doctors and patients better decide if treatment with bupropion will be beneficial or not. To identify possible genetic variations that influence response to bupropion, we will perform genetic tests on blood or saliva specimens from participants receiving treatment with either bupropion or placebo (which is a pill that contains no medication) in conjunction with standard cognitive behavioral therapy drug counseling. We will compare methamphetamine use, as assessed with urine drug screens, among participants receiving bupropion versus those receiving placebo to determine if bupropion helps people to reduce or stop their methamphetamine use. We will then compare the results of the genetic tests among participants who respond and who do not respond to bupropion. In addition, since the amount of methamphetamine a person uses was associated with response to bupropion in preliminary studies, we will also compare the results of genetic testing among persons with heavy versus light methamphetamine use before entering treatment.

Results of this study have the potential to provide insights into the biology of methamphetamine addiction and help increase the understanding of how bupropion works. This information could be useful to develop effective medications for methamphetamine addiction and to improve the ability of clinicians to provide treatment to patients with methamphetamine addiction.
Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • Methamphetamine
  • Amphetamine Dependence
  • Pharmacogenetics
  • Methamphetamine Dependence
  • Substance Abuse
Drug: Bupropion
Bupropion dose will start at 150 mg per day (one 150 mg sustained release tablet per day) for days 1-3 of the first week. The dose will then be increased to 300 mg per day (one 150 mg sustained release tablet twice daily) on day 4 and will remain 300 mg per day until the last week of the medication phase, when the dose will be decreased to 150 mg per day (one 150 mg sustained release tablet per day) for the last three days. The medication treatment phase is for 12 weeks.
Other Names:
  • Zyban
  • Wellbutrin
  • Active Comparator: Bupropion
    Bupropion dose will start at 150 mg per day (one 150 mg sustained release tablet per day) for days 1-3 of the first week. The dose will then be increased to 300 mg per day (one 150 mg sustained release tablet twice daily) on day 4 and will remain 300 mg per day until the last week of the medication phase, when the dose will be decreased to 150 mg per day (one 150 mg sustained release tablet per day) for the last three days.
    Intervention: Drug: Bupropion
  • Placebo Comparator: Sugar Pill
    Intervention: Drug: Bupropion
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
90
July 2013
December 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. 18 years of age or older;
  2. meet DSM-IV criteria for methamphetamine dependence;
  3. seeking treatment for MA problems;
  4. specific range of methamphetamine use in the 30 days prior to study entry;
  5. willing and able to comply with study procedures, including genotyping;
  6. willing and able to provide written informed consent;
  7. if female, not pregnant or lactating and willing to use an acceptable method of barrier birth control (e.g. condoms) during the trial.

Exclusion Criteria:

  1. have a medical condition that, in the study physician's judgment, may interfere with safe study participation (e.g., active TB, unstable cardiac, renal, or liver disease, unstable diabetes);
  2. have a current neurological disorder (e.g., organic brain disease, dementia) or major psychiatric disorder not due to substance abuse (e.g., schizophrenia, bipolar disorder) as assessed by the SCID or a medical history which would make study agent compliance difficult or which would compromise informed consent, or recent (past 30 days) history of suicide attempts and/or current serious suicidal intention or plan as assessed by the SCID;
  3. currently on prescription medication that is contraindicated for use with bupropion;
  4. have current dependence on cocaine, opiates, alcohol, or benzodiazepines as defined by DSM-IV-TR;
  5. have a history of alcohol dependence within the past three years;
  6. have a history of a seizure disorder;
  7. have a medical condition (such as serious head injury) that is associated with increased risk of seizures or on a medication that lowers the seizure threshold;
  8. have a history of anorexia or bulimia;
  9. have current hypertension uncontrolled by medication, or any other circumstances that, in the opinion of the investigators, would compromise participant safety;
  10. have a history of sensitivity to bupropion.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00833443
KH_K23, P50DA018185, K23DA023558, DPMC
Yes
Keith Heinzerling, University of California, Los Angeles
University of California, Los Angeles
National Institute on Drug Abuse (NIDA)
Principal Investigator: Keith G Heinzerling, MD MPH UCLA Dept of Family Medicine
University of California, Los Angeles
January 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP